Mepyramini maleas + Phenylephrini hydrochloridum

Vibrocil, like other sympathomimetics, should be used with caution, particularly in patients who react strongly to adrenergic agents, presenting with symptoms of insomnia, dizziness, tremor, cardiac arrhythmia or raised blood pressure. Vibrocil should not be used for more than 7 consecutive days. Prolonged or excessive use may induce tachyphylaxis and rebound congestion (rhinitis medicamentosa). As with other topical vasoconstrictors, do not exceed the recommended dose; excessive use may lead to systemic vasoconstrictor effects, particularly in young children and elderly patients. Caution is advised in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus and/or in patients with bladder outlet obstruction (such as prostatic hypertrophy). Owing to its content of dimetindene maleate, an H1 antihistamine, Vibrocil should be used with caution in patients with epilepsy. Vibrocil contains benzalkonium chloride. Prolonged use may cause oedema of the nasal mucosa. Vibrocil nasal spray, solution contains 0.015 mg of benzalkonium chloride per 0.140 ml dose, equivalent to 0.106 mg/ml. Vibrocil nasal drops, solution contain 0.0038 mg of benzalkonium chloride per 0.0358 ml drop, equivalent to 0.106 mg/ml. Paediatric population: Vibrocil nasal drops are not intended for the treatment of children under 1 year of age. Vibrocil nasal spray is not intended for the treatment of children under 6 years of age. In children aged 1–12 years, Vibrocil must be administered under the supervision of an adult.